Shares of VYNE Therapeutics VYNE fell 15.2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 57.32% year over year to ($0.35), which were in line with the estimate of ($0.35).
Revenue of $4,258,000 declined by 63.57% from the same period last year, which missed the estimate of $6,210,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
VYNE Therapeutics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 12, 2021
Time: 08:30 AM
ET Webcast URL: https://event.webcasts.com/maintenance.html?ei=1480851&tp_key=06e7c43879
Recent Stock Performance
52-week high: $11.20
Company's 52-week low was at $1.44
Price action over last quarter: down 32.51%
Company Overview
VYNE Therapeutics Inc is a biopharmaceutical company which focuses on the development and commercialization of variety of solutions using its proprietary Molecule Stabilizing Technology. The company is developing products which will help improve lives of the patients with dermatological diseases. Its pipeline includes Amzeeq and Zilxi.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
